Trimodal Deep Learning for Glioma Survival Prediction: A Feasibility Study Integrating Histopathology, Gene Expression, and MRI
Organizations: Department of Computer Science, Munster Technological University, Cork, Ireland
Abstract
Multimodal deep learning has improved prognostic accuracy for brain tumours by integrating histopathology and genomic data, yet the contribution of volumetric MRI within unified survival frameworks remains unexplored. This pilot study extends a bimodal framework by incorporating Fluid Attenuated Inversion Recovery (FLAIR) MRI from BraTS2021 as a third modality. Using the TCGA-GBMLGG cohort (664 patients), we evaluate three unimodal models, nine bimodal configurations, and three trimodal configurations across early, late, and joint fusion strategies. In this small cohort setting, trimodal early fusion achieves an exploratory Composite Score (CS = 0.854), with a controlled CS of +0.011 over the bimodal baseline on identical patients, though this difference is not statistically significant (p = 0.250, permutation test). MRI achieves reasonable unimodal discrimination (CS = 0.755) but does not substantially improve bimodal pairs, while providing measurable uplift in the three-way combination. All MRI containing experiments are constrained to 19 test patients, yielding wide bootstrap confidence intervals (e.g. [0.400,1.000]) that preclude definitive conclusions. These findings provide preliminary evidence that a third imaging modality may add prognostic value even with limited sample sizes, and that additional modalities require sufficient multimodal context to contribute effectively.
Figures & tables
| Experiment | Train | Test | GBM% |
| FFPE Only | 465 | 117 | 36.2% § |
| RNA Only | 389 | 120 | 34.2% § |
| MRI Only | 143 | 19 | 68.5% |
| FFPE + RNA | 376 | 114 | 15.7% |
| RNA + MRI | 47 | 19 | 25.5% |
| FFPE + MRI | 58 | 19 | 15.8% |
| Model | Fusion | Test CS |
| Unimodal | ||
| FFPE | — | 0.773 |
| RNA | — | 0.836 |
| MRI | — | 0.755 ‡ |
| Bimodal | ||
| FFPE + RNA | Early | 0.806 |
| Baseline | + MRI | CS | Note |
|---|---|---|---|
| FFPE (0.773) | FFPE+MRI (0.781) | +0.008 | Uncontrolled ‡ |
| RNA (0.836) | RNA+MRI (0.808) | 0.028 | Uncontrolled ‡ |
| FFPE+RNA (0.806) | Trimodal (0.854) | +0.048 | Uncontrolled |
| FFPE+RNA † (0.843) | Trimodal (0.854) | +0.011 | Controlled |
| † Restricted to same 47/19 patient split as trimodal. | |||
| ‡ Different patient subsets and sample sizes; CS confounded | |||
| Model | Test CI | Parameters | Train CI |
|---|---|---|---|
| Bilinear | 0.819 | 537K | 0.979 |
| Cross-Attention | 0.814 | 1.84M | 0.975 |
| Gated | 0.807 | 3.18M | 0.954 |
| Baseline MLP | 0.801 | 4.2M | 0.95 |
Cancer Survival Prediction
Cancer survival prediction estimates patient outcomes and time to events from clinical, molecular, and medical-imaging data.
See all 92 papers